Literature DB >> 9368614

A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling.

L Alexopoulou1, M Pasparakis, G Kollias.   

Abstract

The arthritogenic activities of tumor necrosis factor (TNF) and its p55TNF-receptor (R) have been well documented in experimental animal models of arthritis, and in transgenic mice expressing wild-type or mutant transmembrane human TNF proteins in their joints. In this study we show that chronic inflammatory arthritis also develops in transgenic mice made to overexpress a mutant transmembrane from of the murine TNF protein (muTNF delta 1-12) which is known to utilize efficiently both the p55 and the p75TNFR. Cross-breeding of the transgene into a TNF knockout background did not alter development of disease. Analysis of TNF bioactivity in sera from lipopolysaccharide-stimulated mice or ex vivo macrophage cultures demonstrated that the muTNF delta 1-12 protein accumulates on the cell surface and is not processed to bioactive soluble TNF, indicating that transmembrane TNF is by itself sufficient to mediate pathogenesis of arthritis. Furthermore, using TNFR knockout mice, it is shown that development of transmembrane TNF-mediated arthritis requires the presence of the p55TNFR but is significantly delayed in the absence of the p75TNFR, suggesting a positive cooperation between the two TNFR in the arthritogenic process. These results indicate that blocking the activities of both soluble and transmembrane TNF may be required to effectively neutralize the pathogenic potential of this cytokine in arthritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368614     DOI: 10.1002/eji.1830271018

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

1.  A place for TACE.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

2.  Transmembrane tumor necrosis factor alpha is required for enteropathy and is sufficient to promote parasite expulsion in gastrointestinal helminth infection.

Authors:  M X Ierna; H E Scales; C Mueller; C E Lawrence
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 3.  Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases.

Authors:  Burkhard Möller; Peter M Villiger
Journal:  Springer Semin Immunopathol       Date:  2006-05-09

4.  An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein.

Authors:  B Pradet-Balade; J P Medema; M López-Fraga; J C Lozano; G M Kolfschoten; A Picard; C Martínez-A; J A Garcia-Sanz; M Hahne
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

5.  Cell-Extrinsic TNF Collaborates with TRIF Signaling To Promote Yersinia-Induced Apoptosis.

Authors:  Lance W Peterson; Naomi H Philip; Christopher P Dillon; John Bertin; Peter J Gough; Douglas R Green; Igor E Brodsky
Journal:  J Immunol       Date:  2016-10-12       Impact factor: 5.422

6.  A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Sara E J Cotterell; Tracey L Mynott; Asiya Tschannerl; Patricia M A Gorak-Stolinska; Paul M Kaye
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 7.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

8.  Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice.

Authors:  Harini Raghu; Alice Jone; Carolina Cruz; Cheryl L Rewerts; Malinda D Frederick; Sherry Thornton; Jay L Degen; Matthew J Flick
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

9.  Protective role of membrane tumour necrosis factor in the host's resistance to mycobacterial infection.

Authors:  Nasiema Allie; Lena Alexopoulou; Valerie J F Quesniaux; Lizette Fick; Ksanthi Kranidioti; George Kollias; Bernhard Ryffel; Muazzam Jacobs
Journal:  Immunology       Date:  2008-06-09       Impact factor: 7.397

10.  Biologic targeting in the treatment of inflammatory bowel diseases.

Authors:  Matteo Bosani; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.